Kian-Huat Lim

26PUBLICATIONS
225CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 04, 2026
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|Apr 20, 2026
Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities.

|Mar 24, 2025
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.

Patrick M Grierson, Crystal Wolf, Rama Suresh

|Oct 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.

Xiuting Liu, John M Baer, Meredith L Stone

|Jun 06, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.

Jeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker

Pageof 5

Frequent Collaborators

6 joint publications

Andrea Wang-Gillam

5 joint publications

David G DeNardo

5 joint publications

Li Ding

5 joint publications

Sherri R Davies